

for this and we assume that it has occurred by chance.

There was a high incidence of death (two of 28) and of cardiac events (nine of 28) in group 3 patients (protocol violators and those with inadequate data). This phenomenon occurred both in active and placebo treated patients and, while our inclusion criteria were primarily designed to prevent inappropriate administration of tocainide, the figures indicate that patients who should be excluded from such investigations are themselves a high risk group. Similar findings have been noted in other studies.^{5,6}

This study is one of very few which has arrived at a firm conclusion regarding the efficacy of a drug for ventricular fibrillation prophylaxis. Further investigations of drug prophylaxis of ventricular fibrillation are required and should employ a study design which permits a positive statistical statement of drug efficacy.

References

- 1 Lie KI, Wellens HJJ, Van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. *N Engl J Med* 1974; **291**: 1324-6.
- 2 Lie KI, Liem KL, Louridtz WL, Janse MJ, Willebrands AF, Durrer D. Efficacy of lignocaine in preventing ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. *Am J Cardiol* 1978; **42**: 486-8.
- 3 Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, DeSanctis RW. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. *N Engl J Med* 1969; **281**: 1253-60.
- 4 Jones DT, Kostuk WJ, Gunton RW. Prophylactic quinidine for the prevention of arrhythmias after acute myocardial infarction. *Am J Cardiol* 1974; **33**: 655-60.
- 5 Campbell RWF, Achuff SC, Pottage A, Murray A, Prescott LF, Julian DG. Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. *J Cardiovasc Pharmacol* 1979; **1**: 43-52.
- 6 Campbell RWF, Bryson LG, Bailey BJ, Murray A, Julian DG. Prophylactic administration of tocainide in acute myocardial infarction. In: Pottage A, Ryden L, eds. *Workshop on tocainide*. Goteborg: AB Hässle, 1981: 201-4.
- 7 Rydén L, Arnman K, Conradson T-B, Hofvendahl S, Mortensen O, Smedgård P. Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. *Am Heart J* 1980; **100**: 1006-12.
- 8 Prescott LF. Pharmacokinetic abnormalities in myocardial infarction. In: Sandøe E, Julian DG, Bell JW, eds. *Management of ventricular tachycardia—role of mexiletine*. Amsterdam: Excerpta Medica, 1978: 465-71.
- 9 Anderson JL, Mason JW, Winkle RA, et al. Clinical electrophysiologic effects of tocainide. *Circulation* 1978; **57**: 685-91.
- 10 Rehnquist N. Comparison of tocainide with lidocaine in AMI. In: Pottage A, Ryden L, eds. *Workshop on tocainide*. Goteborg: AB Hässle, 1981: 187-9.
- 11 Graffner C, Conradson T-B, Hofvendahl S, Rydén L. Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. *Clin Pharmacol Ther* 1980; **27**: 64-71.
- 12 Winkle RA, Meffin PJ, Fitzgerald JW, Harrison DC. Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic agent, tocainide. *Circulation* 1976; **54**: 884-9.
- 13 Moore EN, Spear JF, Horowitz LN, Feldman HS, Moller RA. Electrophysiologic properties of a new antiarrhythmic drug—tocainide. *Am J Cardiol* 1978; **41**: 703-9.
- 14 Young MD, Hadidian Z, Horn HR, Johnson JL, Vassallo HG. Treatment of arrhythmias with oral tocainide. *Am Heart J* 1980; **100**: 1041-5.

Requests for reprints to Dr R W F Campbell, University Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN.

Erratum

The authors regret the following error in their paper in the May issue on "Two dimensional echocardiography and the tricuspid valve. Leaflet definition and prolapse". In the Summary, page 495, line 3, "tricuspid valve prolapse" should read "tricuspid valve regurgitation".